Small Molecules

06 Oct 2020 Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone
06 Oct 2020 NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
06 Oct 2020 Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer
06 Oct 2020 EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)
06 Oct 2020 Cerevel Therapeutics Announces First Patient Dosed in Phase 2 Trial of CVL-865, an Investigational Therapy in Development for the Treatment of Epilepsy
02 Oct 2020 AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
02 Oct 2020 Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients
02 Oct 2020 Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
02 Oct 2020 Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia
02 Oct 2020 Farxiga granted Breakthrough Therapy Designation in US for chronic kidney disease
02 Oct 2020 Debiopharm Launches Trilynx - A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer
01 Oct 2020 Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease
01 Oct 2020 Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin in Dravet Syndrome
01 Oct 2020 IRLAB's mesdopetam IND accepted by the US FDA
01 Oct 2020 Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator
30 Sep 2020 Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
30 Sep 2020 Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)
30 Sep 2020 BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients
30 Sep 2020 Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies
30 Sep 2020 Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
29 Sep 2020 BridgeBio Pharma and affiliate Origin Biosciences announces FDA acceptance of its new drug application for fosdenopterin for the treatment of MoCD Type A
29 Sep 2020 Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
29 Sep 2020 Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
29 Sep 2020 Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
29 Sep 2020 Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up